Skip to main content
Wed, Apr 8, 2026
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
S&P 500 5,142.30 +0.87%|NASDAQ 16,284.75 +1.12%|DOW 38,972.10 -0.23%|AAPL $192.45 +1.80%|TSLA $241.80 -2.10%|AMZN $178.92 +0.54%|GOOGL $141.20 +0.32%|MSFT $415.60 -0.15%|
Sample data
ScienceUnited States3 sourcesNeutral

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 ...

Study will highlight novel iNKT cell-based combinations in checkpoint-refractory diseaseData expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response

MT
mink therapeutics
via Postregister - Corroborated by 2 others
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 ...

Source Verification

Corroboration Score: 3

This story was independently reported by 3 sources. Click any source to read the original article.

Comments

0 comments
Be respectful and constructive.
Loading comments...